; Whereas the management of symptoms of endometriosis may include low-dose oral contraceptives, intrauterine devices (IUDs), painkillers, including nonsteroidal anti-inflammatory drugs (NSAIDs), and gonadotropin-releasing hormone (GnRH) agonist therapy; Whereas in vitro fertilization (IVF) is often recognized as the best option for patients experiencing endometriosis-associated infertility and for whom initial surgery was unsuccessful; Whereas endometriosis is associated with increased health care costs and poses a substantial burden to patients in the health care system; Whereas, in the United States, the estimated average direct health care cost associated with endometriosis per patient is more than $13,000 per year; Whereas 40 percent of women with endometriosis report impaired career growth due to endometriosis, and approximately 50 percent of women with endometriosis experience a decreased ability to work; Whereas the Centers for Disease Control and Prevention found that the average number of bed days for patients with endometriosis was 18 days per year; Whereas women with endometriosis can lose 11 hours per workweek through lost productivity; Whereas the physical and psychological impact of endometriosis affects all domains of life, including social life, relationships, and work; Whereas medical societies and patient groups have expressed the need for greater public attention and updated resources targeted to public education about this unmet health need for women; Whereas there is a need for more research and updated guidelines to treat endometriosis; Whereas there is an ongoing need for additional clinical research and treatment options to manage this debilitating disease; and Whereas there is no known cure for endometriosis: Now, therefore, be it